Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1446 and Donepezil effects on qEEG/ERP in Alzheimer's
NCT01125683Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of azd1446 in Alzheimer's disease (AD), sponsored by AstraZeneca. Started Jun 2010; status: terminated.
02
Drugs
azd1446
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01125683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125683.